CTOs on the Move

Sigtem Technology Inc

www.sigtem.com

 
Sigtem Technology Inc is a Harleysville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sigtem.com
  • 113 Clover Hill Ln
    Harleysville, PA USA 19438
  • Phone: 215.565.6868

Executives

Name Title Contact Details

Similar Companies

LEXEO Therapeutics

LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases.

RoosterBio

RoosterBio is a Maryland-based biotechnology company founded in 2012 and focused on the simplification of translating Cell Therapy and Tissue Engineering technologies into the clinic and onto the market. Regenerative Medicine is showing great promise in the clinic, but the cost, availability, and standardization of the cellular materials from which researchers can perform experiments and clinical trials is holding the field back.

Intrexon Corporation

Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.

BioConvergence

BioConvergence is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tevogen

Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company`s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio`s foundational vision is a healthier world through equitable access to lifesaving innovations.